See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
AdBio Partners is a Paris-based venture capital firm with a strong entrepreneurial spirit, specializing in early-stage investment in the most promising life sciences startups in Europe. The firm acts as a catalyst to create companies based on innovations from academic research, establishing relationships with leading research institutions and technology transfer offices across Europe to source disruptive healthcare innovations in oncology, immunology, ophthalmology, and rare diseases. AdBio Partners combines seed investment with hands-on entrepreneurial support — co-founding companies alongside scientific founders, providing initial funding, building management teams, and guiding R&D strategy. The firm supports innovative therapeutics projects with the potential to deliver first- or best-in-class products addressing high unmet medical needs, leveraging a strong network of scientific, clinical, industrial, and international VC syndicate partners to grow sustainable biotech startups.
Notable quotes
“We firmly believe that our new name, AdBio partners, will further elevate our international positioning as entrepreneur-investors adding value in biotech while referring to our roots at Advent. After the recent first closing of our second fund at €86M, we are well equipped to invest in and build the most promising biotech companies in Europe. The European scientific ecosystem is innovative and rich with high-profile scientists; we aim to leverage its endless potential for breakthrough innovations.”
“Company creation and seed financing in therapeutic biotech companies is challenging but highly rewardable. I am really pleased to fully commit to this underserved venture capital segment, which is in my view the Life Sciences value chain's instrumental stage.”
“AdBio Partners, Europe's leading life sciences seed fund, today announced a number of changes to its management team. These changes are an important step in the strategic and operational development of the management company.”
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| EvlaBio | Seed | $23m | 2025-08-19 |
| ARTHEx Biotech | Series B | $87m | 2025-09-17 |
| Integra Therapeutics | Seed | — | 2025-09-08 |
| Augustine Therapeutics | Series A | $85m | 2025-03-24 |
| Orikine Bio | Seed | $3m | 2026-02-02 |
| Tenpoint Therapeutics | Series B | $85m | 2026-01-28 |
| SparingVision | Seed | — | — |
| AgomAb Therapeutics | Seed | — | — |
| DiogenX | Seed | — | — |
| Alderaan Biotechnology | Seed | — | — |
Frequent co-investors
| VC firm | Deals together |
|---|---|
| Asabys Partners | 4 |
| Kurma Partners | 3 |
| Jeito Capital | 3 |
| Bpifrance | 3 |
| V-Bio Ventures | 2 |
| Sofinnova Partners | 2 |
Fit check
Is AdBio Partners a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit